Kaplan-Meier cumulative event plots comparing the primary study outcomes. (A) compares rates of any stroke or systemic embolism (SE) for patients receiving apixaban, dabigatran, and rivaroxaban. (B) compares rates of any major bleeding between patients receiving apixaban, dabigatran, and rivaroxaban.